POV: you are a biotech innovator with a breakthrough biologic or diagnostic platform. Building your own R&D infrastructure from hires, labs and certifications can cost $2–5 million and take 18–24 months. Every week of delay is market share and funding left on the table.

We flip that model. As India’s first manufacturer of pharmacokinetics (PK) and immunogenicity ELISA kits, Denovo Biolabs offers end-to-end gene & protein services, antibody development, cell-based assays, and lateral-flow diagnostics. When integrated with ISO-certified workflows, validated instrumentation and expert teams, you can save up to 80 percent of capital expenditure.

Now, let us see how we can be a right fit.

Our Intro

• Founded: 2013 in Bengaluru, Karnataka
• Headquarters: IBAB Campus, Electronics City Phase-1, Bengaluru
• Team Size: 11–50 employees, including PhD-level scientists and industry veterans (View on LinkedIn)
• Specialty: R&D products & services for large-molecule therapeutics, biosimilar development, and in vitro diagnostics
• Certifications: ISO-quality systems, GLP-compliant labs, robust data-integrity protocols
• USP: First Indian company to launch PK & immunogenicity ELISA kits for biopharma research

Our Core Services

1 Gene & Protein Services

• Custom gene synthesis with codon optimisation for your expression host
• Recombinant protein expression in E. coli, yeast or mammalian systems
• Purification & characterisation using HPLC, mass spectrometry and bioanalyser platforms

USP: Precise control from sequence design through purified protein ensures reproducibility and regulatory compliance.

2 Antibody Development

• Monoclonal & polyclonal workflows: hybridoma generation, animal immunization, screening
• Host selection: mice, rabbits, goats—tailored to affinity, specificity and volume needs
• Conjugation services: HRP, biotin, fluorescent labels for ELISA, flow cytometry, imaging

USP: High-quality antibodies are the linchpin of immunoassays, therapeutic research and diagnostic products.

3 Cell-Based Assays

• Neutralization & potency tests: measure therapeutic activity in biologically relevant systems
• MTT/XTT cytotoxicity assays: first-line safety screening
• Mechanism-of-action studies: pathway activation, receptor binding analyses

USP: Translational assays bridge molecular innovation to clinical relevance, de-risking development.

4 Lateral-Flow Assays

• Design & prototyping: strip format, sample & conjugate pads, nitrocellulose membranes
• Gold nanoparticle & bead conjugation for enhanced signal intensity
• Field-validation across diverse clinical sites

USP: Rapid, point-of-care diagnostics transform patient care. Our end-to-end capabilities get your lateral-flow product ready for market faster.

Our Product Portfolio

Beyond custom services, Denovo Biolabs offers an off-the-shelf catalogue trusted by biopharma and academia:

• Biosimilar PK ELISA Kits & Immunogenicity Kits
• Cytokine & Small-Molecule ELISA Kits
• Recombinant Proteins (cytokines, growth factors)
• Primary & Secondary Antibodies, Diagnostic Antibodies
• Assay Reagents, Cell Culture Media, Normal Serum/IgG

Every lot undergoes stringent QC for sensitivity, specificity and lot-to-lot consistency

Our Impact

1. Accelerated Biosimilar PK Analysis
   • Challenge: Global biopharma client needed robust PK assays for an adalimumab biosimilar.
   • Solution: Delivered validated PK ELISA kits and turnkey assay support.
   • Result: Regulatory submission-ready data in 8 weeks vs. 5 months expected.
2. High-Throughput Cytokine Panel
   • Challenge: Academic consortium required multiplexed cytokine quantification.
   • Solution: Custom cytokine ELISA panels and automation compatibility.
   • Result: Data generation ramped from 20 to 200 samples/day—fourfold throughput.
3. Point-of-Care Diagnostic Rollout
   • Challenge: Startup needed a lateral-flow strip for rapid infectious disease detection.
   • Solution: Full design, nanoparticle conjugation, and multi-site field validation.
   • Result: CE-mark registration and launch in <9 months.

Our Impact

Criterion	Denovo Biolabs	In-House Build
Ramp-Up Time	2–4 weeks	18–24 months
CapEx	$400–800 K	$2–5 M+
Regulatory Readiness	ISO/GLP in place	+12 months to certify
Technical Expertise	PhD scientists, decades of experience	Hiring/training required
Scalability	Seamless from R&D to small-batch	New capital investment needed

Partnering with Denovo means reassigning your internal resources back to core discovery—and accelerating every subsequent milestone..

Ready to transform your scientific vision into market success?

📅 Schedule your free consultation

🔗 Explore our product catalogue

Partner with the innovators—partner with Denovo Biolabs.